Efficacy and safety of immunological checkpoint inhibitors combined with anti-angiogenic drugs in first-line treatment of metastatic renal cell carcinoma: a systematic review and meta-analysis

BACKGROUND: Immune checkpoint inhibitors (ICIs) have shown promising results for the second-line treatment of metastatic renal cell carcinoma (mRCC). Several randomized controlled trials have so far also evaluated the efficacy of ICIs for first-line treatment of mRCC. In this study, we conducted a m...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Yingwei, Chen, Zhiliang, Zhong, Qiyu, Chen, Yuqing, Shangguan, Wentai, Xie, Wenlian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7844504/
https://www.ncbi.nlm.nih.gov/pubmed/33532319
http://dx.doi.org/10.21037/tau-20-969

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7844504/
https://www.ncbi.nlm.nih.gov/pubmed/33532319
http://dx.doi.org/10.21037/tau-20-969

Ejemplares similares